In vivo bypass of hemophilia A coagulation defect by Factor XIIa implant

[1]  P. Soon-Shiong,et al.  Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation , 1994, The Lancet.

[2]  S. Rasmussen,et al.  Pharmacokinetics of Recombinant Factor VIIa in the Rat – A Comparison of Bio-, Immuno- and Isotope Assays , 1993, Thrombosis and Haemostasis.

[3]  A. Bloom,et al.  Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[4]  U. Hedner,et al.  Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. , 1993, Transfusion medicine reviews.

[5]  S. Glazer,et al.  Experience with recombinant factor VIIA in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. , 1993, The American journal of pediatric hematology/oncology.

[6]  J. Jesty,et al.  Factor VIIA levels in patients with hemophilia. , 1992, Blood.

[7]  Robert Lanza,et al.  Islet Transplantation With Immunoisolation , 1992, Diabetes.

[8]  R. Lanza,et al.  Perspectives in diabetes. Islet transplantation with immunoisolation. , 1992, Diabetes.

[9]  U. Hedner,et al.  Management of hemophilia patients with inhibitors. , 1992, Hematology/oncology clinics of North America.

[10]  A. Monaco,et al.  Islet transplantation using an immunoprotective membrane in dogs that have undergone a pancreatectomy. , 1992, ASAIO journal.

[11]  Y. Nemerson,et al.  Measurement of basal levels of factor VIIa in hemophilia A and B patients. , 1992, Blood.

[12]  S. Schulman.  A therapeutic alternative for haemophiliacs with inhibitors , 1992, Acta paediatrica.

[13]  A. Bloom.  Management of factor VIII inhibitors: evolution and current status. , 1992, Haemostasis.

[14]  A. Bloom.  Progress in the Clinical Management of Haemophilia , 1991, Thrombosis and Haemostasis.

[15]  S. Glazer,et al.  PROLONGED RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) TREATMENT FOR SEVERE BLEEDING IN A FACTOR‐IX‐DEFICIENT PATIENT WITH AN INHIBITOR , 1991, British journal of haematology.

[16]  C. Kasper.  Complications of Hemophilia A Treatment: Factor VIII Inhibitors a , 1991, Annals of the New York Academy of Sciences.

[17]  Thompson Ar.  Molecular biology of the hemophilias. , 1991 .

[18]  U. Hedner.  Experiences with recombinant factor VIIa in haemophiliacs. , 1991, Current studies in hematology and blood transfusion.

[19]  A. Rehemtulla,et al.  The molecular biology of initiation of coagulation by tissue factor. , 1991, Current studies in hematology and blood transfusion.

[20]  A. Thompson.  Molecular biology of the hemophilias. , 1991, Progress in hemostasis and thrombosis.

[21]  P. Simioni,et al.  Factor VII and haemostasis: interaction between abnormal factors VII and tissue thromboplastins. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  U. Hedner.  Factor VIIa in the treatment of haemophilia. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  Y. Sultan,et al.  Treatment of factor VIII inhibitors. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  D. Monroe,et al.  Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. , 1989, Thrombosis research.

[25]  H. Roberts,et al.  Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor , 1989, American journal of hematology.

[26]  S. Rapaport,et al.  Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. , 1989, Blood.

[27]  S. Rapaport,et al.  Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables. , 1989, Blood.

[28]  E. Regoeczi,et al.  Absorption of plasma proteins from peritoneal cavity of normal rats. , 1989, The American journal of physiology.

[29]  S. Rapaport,et al.  Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. , 1989, Blood.

[30]  M. Read,et al.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Tengborn,et al.  Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. , 1989, Haemostasis.

[32]  K. Mann,et al.  A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo , 1988, British journal of haematology.

[33]  P. Sandset,et al.  The inhibitor of F VIIa in plasma measured with a sensitive chromogenic substrate assay: comparison with antithrombin, protein C and heparin cofactor II in a clinical material. , 1988, Folia haematologica.

[34]  S. Rapaport,et al.  Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). , 1987, Thrombosis research.

[35]  A. Giles.  By what mechanisms could prothrombin complex concentrates promote factor VIII bypassing activity in vivo? , 1987, Transfusion medicine reviews.

[36]  W. Kisiel,et al.  Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. , 1983, The Journal of clinical investigation.

[37]  S. Shapiro,et al.  Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. , 1980, The New England journal of medicine.

[38]  P. Majerus,et al.  Purification and properties of human coagulation factor VII. , 1980, The Journal of biological chemistry.

[39]  K. Fujikawa,et al.  Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). , 1977, Biochemistry.

[40]  J. Penner,et al.  Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. , 1976, JAMA.

[41]  A. Pollock,et al.  Letter: Factor-VIII inhibitor bypassing activity. , 1976, Lancet.

[42]  J. Penner,et al.  Activated prothrombin concentrate for patients with factor VIII inhibitors. , 1974, The New England journal of medicine.

[43]  Henry Wl.  Perspectives in diabetes. , 1962 .

[44]  L. Went,et al.  Sickle cell-thalassemia disease in Jamaica. , 1958, Blood.